Receptor tyrosine kinase signaling favors a protumorigenic state in breast cancer cells by inhibiting the adaptive immune response

Josie Ursini-Siegel, Sean Cory, Dongmei Zuo, William R. Hardy, Elton Rexhepaj, Sonya Lam, Babette Schade, Karin Jirstrom, Eva Bjur, Ciriaco A. Piccirillo, David DeNardo, Lisa Coussens, Donal J. Brennan, William M. Gallagher, Morag Park, Tony Pawson, Michael Hallett, William J. Muller

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Using transgenic mouse models of breast cancer that ablate Src homology and collagen A (ShcA) expression or oncogene-coupled ShcA signaling, we previously showed that this adaptor is critical for mammary tumor onset and progression. We now provide the first evidence that ShcA regulates mammary tumorigenesis, in part, through its ability to regulate the adaptive immune response. Inactivation of ShcA signaling within tumor cells results in extensive CD4+ T-cell infiltration and induction of a humoral immune response in mammary tumors. This is associated with a robust CTL response in preneoplastic lesions that are deficient in ShcA signaling. Moreover, mammary tumor progression of ShcA-deficient hyperplasias is accelerated in a T cell - deficient background. We also uncover a clinically relevant correlation between high ShcA expression and low CTL infiltration in human breast cancers. Finally, we define a novel ShcA-regulated immune signature that functions as an independent prognostic marker of survival in human epidermal growth factor receptor 2+ and basal breast cancers. We reveal a novel role for tumor cell - derived ShcA in the establishment and maintenance of an immunosuppressive state.

Original languageEnglish (US)
Pages (from-to)7776-7787
Number of pages12
JournalCancer Research
Volume70
Issue number20
DOIs
StatePublished - Oct 15 2010
Externally publishedYes

Fingerprint

Receptor Protein-Tyrosine Kinases
Adaptive Immunity
Collagen
Breast Neoplasms
src Genes
T-Lymphocytes
Immunosuppressive Agents
Humoral Immunity
Transgenic Mice
Hyperplasia
Neoplasms
Carcinogenesis
Breast
Maintenance
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Receptor tyrosine kinase signaling favors a protumorigenic state in breast cancer cells by inhibiting the adaptive immune response. / Ursini-Siegel, Josie; Cory, Sean; Zuo, Dongmei; Hardy, William R.; Rexhepaj, Elton; Lam, Sonya; Schade, Babette; Jirstrom, Karin; Bjur, Eva; Piccirillo, Ciriaco A.; DeNardo, David; Coussens, Lisa; Brennan, Donal J.; Gallagher, William M.; Park, Morag; Pawson, Tony; Hallett, Michael; Muller, William J.

In: Cancer Research, Vol. 70, No. 20, 15.10.2010, p. 7776-7787.

Research output: Contribution to journalArticle

Ursini-Siegel, J, Cory, S, Zuo, D, Hardy, WR, Rexhepaj, E, Lam, S, Schade, B, Jirstrom, K, Bjur, E, Piccirillo, CA, DeNardo, D, Coussens, L, Brennan, DJ, Gallagher, WM, Park, M, Pawson, T, Hallett, M & Muller, WJ 2010, 'Receptor tyrosine kinase signaling favors a protumorigenic state in breast cancer cells by inhibiting the adaptive immune response', Cancer Research, vol. 70, no. 20, pp. 7776-7787. https://doi.org/10.1158/0008-5472.CAN-10-2229
Ursini-Siegel, Josie ; Cory, Sean ; Zuo, Dongmei ; Hardy, William R. ; Rexhepaj, Elton ; Lam, Sonya ; Schade, Babette ; Jirstrom, Karin ; Bjur, Eva ; Piccirillo, Ciriaco A. ; DeNardo, David ; Coussens, Lisa ; Brennan, Donal J. ; Gallagher, William M. ; Park, Morag ; Pawson, Tony ; Hallett, Michael ; Muller, William J. / Receptor tyrosine kinase signaling favors a protumorigenic state in breast cancer cells by inhibiting the adaptive immune response. In: Cancer Research. 2010 ; Vol. 70, No. 20. pp. 7776-7787.
@article{038f338c9b304893812960e028c2acc5,
title = "Receptor tyrosine kinase signaling favors a protumorigenic state in breast cancer cells by inhibiting the adaptive immune response",
abstract = "Using transgenic mouse models of breast cancer that ablate Src homology and collagen A (ShcA) expression or oncogene-coupled ShcA signaling, we previously showed that this adaptor is critical for mammary tumor onset and progression. We now provide the first evidence that ShcA regulates mammary tumorigenesis, in part, through its ability to regulate the adaptive immune response. Inactivation of ShcA signaling within tumor cells results in extensive CD4+ T-cell infiltration and induction of a humoral immune response in mammary tumors. This is associated with a robust CTL response in preneoplastic lesions that are deficient in ShcA signaling. Moreover, mammary tumor progression of ShcA-deficient hyperplasias is accelerated in a T cell - deficient background. We also uncover a clinically relevant correlation between high ShcA expression and low CTL infiltration in human breast cancers. Finally, we define a novel ShcA-regulated immune signature that functions as an independent prognostic marker of survival in human epidermal growth factor receptor 2+ and basal breast cancers. We reveal a novel role for tumor cell - derived ShcA in the establishment and maintenance of an immunosuppressive state.",
author = "Josie Ursini-Siegel and Sean Cory and Dongmei Zuo and Hardy, {William R.} and Elton Rexhepaj and Sonya Lam and Babette Schade and Karin Jirstrom and Eva Bjur and Piccirillo, {Ciriaco A.} and David DeNardo and Lisa Coussens and Brennan, {Donal J.} and Gallagher, {William M.} and Morag Park and Tony Pawson and Michael Hallett and Muller, {William J.}",
year = "2010",
month = "10",
day = "15",
doi = "10.1158/0008-5472.CAN-10-2229",
language = "English (US)",
volume = "70",
pages = "7776--7787",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "20",

}

TY - JOUR

T1 - Receptor tyrosine kinase signaling favors a protumorigenic state in breast cancer cells by inhibiting the adaptive immune response

AU - Ursini-Siegel, Josie

AU - Cory, Sean

AU - Zuo, Dongmei

AU - Hardy, William R.

AU - Rexhepaj, Elton

AU - Lam, Sonya

AU - Schade, Babette

AU - Jirstrom, Karin

AU - Bjur, Eva

AU - Piccirillo, Ciriaco A.

AU - DeNardo, David

AU - Coussens, Lisa

AU - Brennan, Donal J.

AU - Gallagher, William M.

AU - Park, Morag

AU - Pawson, Tony

AU - Hallett, Michael

AU - Muller, William J.

PY - 2010/10/15

Y1 - 2010/10/15

N2 - Using transgenic mouse models of breast cancer that ablate Src homology and collagen A (ShcA) expression or oncogene-coupled ShcA signaling, we previously showed that this adaptor is critical for mammary tumor onset and progression. We now provide the first evidence that ShcA regulates mammary tumorigenesis, in part, through its ability to regulate the adaptive immune response. Inactivation of ShcA signaling within tumor cells results in extensive CD4+ T-cell infiltration and induction of a humoral immune response in mammary tumors. This is associated with a robust CTL response in preneoplastic lesions that are deficient in ShcA signaling. Moreover, mammary tumor progression of ShcA-deficient hyperplasias is accelerated in a T cell - deficient background. We also uncover a clinically relevant correlation between high ShcA expression and low CTL infiltration in human breast cancers. Finally, we define a novel ShcA-regulated immune signature that functions as an independent prognostic marker of survival in human epidermal growth factor receptor 2+ and basal breast cancers. We reveal a novel role for tumor cell - derived ShcA in the establishment and maintenance of an immunosuppressive state.

AB - Using transgenic mouse models of breast cancer that ablate Src homology and collagen A (ShcA) expression or oncogene-coupled ShcA signaling, we previously showed that this adaptor is critical for mammary tumor onset and progression. We now provide the first evidence that ShcA regulates mammary tumorigenesis, in part, through its ability to regulate the adaptive immune response. Inactivation of ShcA signaling within tumor cells results in extensive CD4+ T-cell infiltration and induction of a humoral immune response in mammary tumors. This is associated with a robust CTL response in preneoplastic lesions that are deficient in ShcA signaling. Moreover, mammary tumor progression of ShcA-deficient hyperplasias is accelerated in a T cell - deficient background. We also uncover a clinically relevant correlation between high ShcA expression and low CTL infiltration in human breast cancers. Finally, we define a novel ShcA-regulated immune signature that functions as an independent prognostic marker of survival in human epidermal growth factor receptor 2+ and basal breast cancers. We reveal a novel role for tumor cell - derived ShcA in the establishment and maintenance of an immunosuppressive state.

UR - http://www.scopus.com/inward/record.url?scp=78049271279&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78049271279&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-10-2229

DO - 10.1158/0008-5472.CAN-10-2229

M3 - Article

C2 - 20924104

AN - SCOPUS:78049271279

VL - 70

SP - 7776

EP - 7787

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 20

ER -